|
private:calixar
|
1464385
|
May 23rd, 2019 12:00AM
|
CALIXAR
|
854
|
9.00
|
Open
|
Biotechnology
|
May 22nd, 2019 09:10PM
|
May 22nd, 2019 09:10PM
|
CALIXAR, is a French biotech company specialized in the functional and native isolation of complex therapeutic targets and antigens
We develop and implement chemistry and biochemistry tools to isolate in solution - with the highest purity levels - full-length membrane proteins, while keeping their structural and functional integrity. Our approach represents the opportunity for pharmaceutical companies to start and work with high quality targets or antigens before developing antibodies, formulating vaccines and/or discovering a primary lead through Structure Based Drug Design or High Throughput Screening assays.
As membrane proteins represent more than 60% of pharmaceuticals drug targets, to keep their native conformation during the extraction from membrane cells and solubilization is crucial within the process of targets selection.
Our technological platform preserves the original structure of membrane proteins such as GPCRs, Ion channels, Transporters, Viral targets, enzymes, etc.) or others native receptors acting as drug targets or antigens. As a result, this most accurate targeting helps biotechs, academic teams, pharmaceutical industries to develop highly potential drugs, bio drugs and vaccines and consequently saves significant time and money in further clinical stages.
By using original chemistry and specific approaches designed on demand, we develop new tools and protocols for the identification, expression, extraction, purification and crystallization of these membrane proteins/antigens from cells or from endogenous materials (virus, bacteria, primary cells, organs, etc.).
For structure based drug design approaches, we carry out crystallization tests and structure determination of these native targets starting from their full-length and functional version without any point mutations or deletions.
CALIXAR sets up specific R&D programs with its customers using classical and flexible business model: Fee for service, Risk sharing, Exclusivity option and Licensing out.
|
Open
|
Membrane Protein, Vaccine discovery, Structure Based Drug Design, Target validation, GPCR, Ion channel, Transporter, Therapeutic antibodies, Therapeutic Targets, Isolation, Expression, Purification, Crystallization, Stabilization, Extraction, Native receptors, Chemistry
|
Open
|
60 AVENUE ROCKEFELLER
|
LYON
|
|
FR
|
69008
|
|
Calixar
|
|
Pharmaceuticals & Biotechnology
|
|
private:calixar
|
1464385
|
Nov 7th, 2017 12:00AM
|
CALIXAR
|
591
|
12.00
|
Open
|
Biotechnology
|
Nov 7th, 2017 06:28PM
|
Nov 7th, 2017 06:28PM
|
CALIXAR, is a French biotech company specialized in the functional and native isolation of complex therapeutic targets and antigens
We develop and implement chemistry and biochemistry tools to isolate in solution - with the highest purity levels - full-length membrane proteins, while keeping their structural and functional integrity. Our approach represents the opportunity for pharmaceutical companies to start and work with high quality targets or antigens before developing antibodies, formulating vaccines and/or discovering a primary lead through Structure Based Drug Design or High Throughput Screening assays.
As membrane proteins represent more than 60% of pharmaceuticals drug targets, to keep their native conformation during the extraction from membrane cells and solubilization is crucial within the process of targets selection.
Our technological platform preserves the original structure of membrane proteins such as GPCRs, Ion channels, Transporters, Viral targets, enzymes, etc.) or others native receptors acting as drug targets or antigens. As a result, this most accurate targeting helps biotechs, academic teams, pharmaceutical industries to develop highly potential drugs, bio drugs and vaccines and consequently saves significant time and money in further clinical stages.
By using original chemistry and specific approaches designed on demand, we develop new tools and protocols for the identification, expression, extraction, purification and crystallization of these membrane proteins/antigens from cells or from endogenous materials (virus, bacteria, primary cells, organs, etc.).
For structure based drug design approaches, we carry out crystallization tests and structure determination of these native targets starting from their full-length and functional version without any point mutations or deletions.
CALIXAR sets up specific R&D programs with its customers using classical and flexible business model: Fee for service, Risk sharing, Exclusivity option and Licensing out.
|
|
|
|
|
|
|
|
|
|
Calixar
|
|
Pharmaceuticals & Biotechnology
|
|
private:calixar
|
1464385
|
Nov 1st, 2017 12:00AM
|
CALIXAR
|
590
|
12.00
|
Open
|
Biotechnology
|
Nov 1st, 2017 06:04AM
|
Nov 1st, 2017 06:04AM
|
CALIXAR, is a French biotech company specialized in the functional and native isolation of complex therapeutic targets and antigens
We develop and implement chemistry and biochemistry tools to isolate in solution - with the highest purity levels - full-length membrane proteins, while keeping their structural and functional integrity. Our approach represents the opportunity for pharmaceutical companies to start and work with high quality targets or antigens before developing antibodies, formulating vaccines and/or discovering a primary lead through Structure Based Drug Design or High Throughput Screening assays.
As membrane proteins represent more than 60% of pharmaceuticals drug targets, to keep their native conformation during the extraction from membrane cells and solubilization is crucial within the process of targets selection.
Our technological platform preserves the original structure of membrane proteins such as GPCRs, Ion channels, Transporters, Viral targets, enzymes, etc.) or others native receptors acting as drug targets or antigens. As a result, this most accurate targeting helps biotechs, academic teams, pharmaceutical industries to develop highly potential drugs, bio drugs and vaccines and consequently saves significant time and money in further clinical stages.
By using original chemistry and specific approaches designed on demand, we develop new tools and protocols for the identification, expression, extraction, purification and crystallization of these membrane proteins/antigens from cells or from endogenous materials (virus, bacteria, primary cells, organs, etc.).
For structure based drug design approaches, we carry out crystallization tests and structure determination of these native targets starting from their full-length and functional version without any point mutations or deletions.
CALIXAR sets up specific R&D programs with its customers using classical and flexible business model: Fee for service, Risk sharing, Exclusivity option and Licensing out.
|
|
|
|
|
|
|
|
|
|
Calixar
|
|
Pharmaceuticals & Biotechnology
|